The company does not believe that the warning letter will have an impact on disruption of supplies or the existing revenues from operations of this facility
In the next six months, the program aims to screen 4,000 women from underprivileged communities in and around Mathura
The companies have also initiated a Phase 1/2/3 study NCT05543616 to evaluate the safety, tolerability, and immunogenicity of different doses
Transformation to pure-play Innovative Medicines company nears completion
RYALTRIS is a fixed-dose combination therapy that provides relief for the symptoms of SAR, both nasal and ocular, in one easy-to-use nasal spray
The company has received payment towards completion of sale of the first tranche from Sekhmet Pharmaventures Private Limited.
To set up 50 lifestyle modification centres across the UAE in the next 24 months
Diclofenac Sodium Topical Solution USP, 2% w/w (RLD Pennsaid) had estimated annual sales of US $484 million in the US
The facility is identified as a testing laboratory in numerous ANDAs filed by Shilpa Medicare Limited and its agreed parties
Our strategy to drive therapy and brand-focused expansion will continue to show results, especially in the domestic business.
Subscribe To Our Newsletter & Stay Updated
